Gland Pharma shares will be in focus after its subsidiary Cenexi received 11 observations from France’s ANSM following a GMP inspection at its Fontenay facility. The company clarified that operations remain unaffected and a CAPA plan has been accepted. Gland Pharma shares have risen 16% in a month, though the stock is still down 43% over three years.